Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.
Our adviser: Drugs Infromation online
Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.
Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.
Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.
Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.
Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.
NAVIGATION
|
2
Apr |
Simple Test To Identify MRSA In Wounds Could Quickly Diagnose The Superbug And Help Prevent SpreadCategory: MRSA / Drug Resistance | Leave a Comment |
The test, developed at the University of Edinburgh in collaboration with NHS Lothian, works by taking swabs from a wound or sores. These are then analysed using a strip with electrical sensors that can detect MRSA. Researchers currently process the swab samples in the laboratory to increase the amount of bacteria present before testing them…
|
25
Nov |
First Healthcare-Associated Infection Assay On The BD MAX™ System Launches In EuropeCategory: MRSA / Drug Resistance | Leave a Comment |
BD Diagnostics, a segment of BD (Becton, Dickinson and Company), announced that it obtained CE Marking for the BD MAX™ MRSA Assay to rapidly and accurately identify methicillin-resistant Staphylococcus aureus (MRSA) in patients. Rapid and accurate information enables infection control measures to be implemented faster which can positively impact patient management…
|
25
May |
Rapid Diagnosis Of MRSA InfectionsCategory: MRSA / Drug Resistance | Leave a Comment |
The latest episode in the American Chemical Society’s (ACS) award-winning podcast series, “Global Challenges/Chemistry Solutions,” focuses on new blood test that can quickly tell whether patients are infected with an antibiotic-resistant bacterium that’s become a global threat, significantly improving treatment…
|
8
May |
Rapidly Diagnosing And Identifying MRSA From MSSA, FDA Clears First TestCategory: MRSA / Drug Resistance | Leave a Comment |
Staphylococcus aureus infections can be resistant to methicillin - an antibiotic - or susceptible to it. MRSA is resistant to methicillin while MSSA is susceptible. The Food and Drug Administration (FDA) has cleared the first test - the KeyPath MRSA/MSSA Blood Culture Test - that can tell one from the other rapidly…
|
23
Mar |
Active Ingredient From Chinese Medicine Blocks Biofilm Formation On Medical Implant MaterialsCategory: MRSA / Drug Resistance | Leave a Comment |
A compound that is an active ingredient in plants commonly used in Chinese medicine prevents biofilm formation on polystyrene and polycarbonate surfaces by Staphylococcus aureus. The research suggests that this compound, 1,2,3,4,6-Penta-O-galloyl-beta-D-glucopyranose (PGG) is highly promising for clinical use in preventing biofilm formation by S. aureus…
|
26
Jan |
Spin-Out To Apply New Technology For Tackling InfectionCategory: MRSA / Drug Resistance | Leave a Comment |
A new company has been launched to commercialise an award-winning technology, developed at Strathclyde, for tackling bacterial infection and contamination, including superbugs such as MRSA…
|
10
Dec |
Automated UV-C Device Reduces Infectious Pathogens In Hospital Patient Rooms By More Than 99.9% In Only 15 MinutesCategory: MRSA / Drug Resistance | Leave a Comment |
Results of an eight-month hospital study, “Room Decontamination with UV Radiation,” were published in the October 2010 issue of “Infection Control and Hospital Epidemiology.” The study evaluated the ability of an automated UV device, Tru-D, to decontaminate patient rooms contaminated with MRSA, VRE, C. difficile and a MDR strain of Acinetobacter baumannii. The research team of William A…
|
4
Nov |
Molecular Detection Inc. Awarded $244,500 Federal Grant To Support US Validation Trial For Its Detect-Ready™ MRSA Screening PanelCategory: MRSA / Drug Resistance | Leave a Comment |
Molecular Detection Inc. (MDI), a company developing Detect-Ready™ tests designed to increase the speed and accuracy of infectious disease diagnosis, announced that it has been awarded a $244,500 federal Therapeutic Discovery Project grant…
|
21
Oct |
Killing Antibiotic-Resistant Staph Bacteria With Fluorescent LightCategory: MRSA / Drug Resistance | Leave a Comment |
The prevalence of methicillin-resistant Staphylococcus aureus (MRSA) infections is well known, causing an estimated 19,000 deaths and $3-4 billion in healthcare costs per year in the U.S…
|
14
Oct |
Molecular Detection’s Detect-Ready™ MRSA Assay Demonstrates Strong Performance In Independent Comparative Study From Leading UK HospitalCategory: MRSA / Drug Resistance | Leave a Comment |
Molecular Detection Inc. (MDI), a company developing Detect-Ready™ assays designed to increase the speed and accuracy of infectious disease diagnosis, announced that its Detect-Ready MRSA assay has received its first independent validation in a study conducted at St. George’s Healthcare NHS Trust, a leading teaching hospital in the UK…